Metformin
Lipodystrophy
Floatz Rating
BBB74/100
Confidence
Indicative
Sponsor
Hospital Civil de Guadalajara
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04860063CT.gov Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. | — | Unknown | — | — | — |
NCT01612858CT.gov Metabolic Abnormalities in HIV-infected Persons | — | Completed | — | — | — |
NCT00362440CT.gov Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome | — | Completed | — | — | — |
NCT00015691CT.gov Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lipodystrophy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Metformin (this asset) | Hospital Civil de Guadalajara | Approved | BBB · 74 |
| Efavirenz | Juan A. Arnaiz | P4 | A |
| Lamivudine | Thomas Benfield | P4 | BBB |
| Abacavir | Kirby Institute | P4 | BBB |
| Pravastatin | Kirby Institute | P4 | BBB |
| Retrovir | Kirby Institute | P4 | BBB |
| Nevirapine Anhydrous | Kirby Institute | P4 | BBB |
| Pioglitazone | Tufts Medical Center | P4 | BBB |
| Dolutegravir | Thomas Benfield | P4 | BBB |
+28 more in the Lipodystrophy cohort
Other indications for Metformin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prediabetes Syndrome | — | P4 | A · 81 |
| Gestational Diabetes | — | P4 | A · 81 |
| Diabetes Mellitus | — | P4 | A · 80 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Metformin in Lipodystrophy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/metformin-lipodystrophy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →